Is there any price change or price reduction trend of selumetinib in 2025?

As of2025, selumetinib (Selumetinib) has been officially launched in mainland China and has been included in the national medical insurance directory, indicating that its clinical use in the treatment of NF1 (neurofibromatosis) and other diseases has received policy-level support. Domestic patients can purchase the drug through regular hospitals or pharmacies, which greatly improves drug accessibility. As they enter the scope of medical insurance reimbursement, eligible patients can enjoy part or most of the drug fee reductions. For specific reimbursement ratios, please consult the local hospital or medical insurance agency.

The price of selumetinib after its domestic launch is approximately more than 10,000 yuan per box. Although the price is still moderately high compared to some imported targeted drugs, after medical insurance reimbursement, the patient's out-of-pocket expenses are significantly reduced. For patients who have used the drug for a long time, the addition of medical insurance has eased the financial burden to a certain extent. However, due to differences in medical insurance policies in various places, it is recommended that patients learn more about local policies to ensure they receive the optimal reimbursement plan during medication.

At present, the domestic price of selumetinib has not shown significant fluctuations or official price reduction information. Since it has just entered the medical insurance catalog, the possibility of significant price adjustments in the short term is low. However, with the update of the medical insurance negotiation cycle and the intensification of market competition, there will be room for price adjustment in the future. The industry generally predicts that if more generic drugs come out or policies promote medical insurance price reduction negotiations, the drug may usher in new price reduction opportunities in the future.

For patients with a heavy financial burden or who are unable to be covered by medical insurance in time, they may also consider obtaining the generic selumetinib produced in Laos through formal channels. The price of this generic version is about 2000 RMB. It has basically the same ingredients as the original drug and has received positive feedback from many patients in terms of therapeutic effects. Although generic drugs have slightly different quality control and approval processes, they are a more economical and practical alternative for patients who require long-term medication, provided they are obtained through trusted channels to ensure drug safety and compliance.

Reference materials:https://www.drugs.com/